Results 101 to 110 of about 69,154 (279)

P-148 Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling [PDF]

, 2021
Chiara Morelli, Vincenzo Formica, Elena Doldo, Silvia Riondino, M. Rofei, Giampiero Palmieri, Augusto Orlandi, Mario Roselli   +7 more
openalex   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Redox regulation by sulfiredoxin-1: bridging cysteine oxidation and liver disease therapeutics

Experimental and Molecular Medicine
Cysteine (Cys) posttranslational modifications play a critical role in regulating protein function, cellular signaling and redox homeostasis in various physiological and pathological conditions.
Jong-Won Kim, Mengyun Ke, Donovan Whitfield, Bin Yang, Gu Seob Roh, Wen Xie   +5 more
doaj   +1 more source

Drug Points: Apparent interaction between warfarin and levonorgestrel used for emergency contraception [PDF]

, 2000
No abstract ...
Ellison, J., Greer, I.A., Thomson, A.J., Walker, I.D.   +3 more
core   +2 more sources

A model‐based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs

British Journal of Pharmacology, EarlyView.
Background The activity of CYP2C9, an important drug metabolism enzyme, is subject to the impact of genetic polymorphism. The single nucleotide polymorphism *3 is significantly associated with the increased exposure of CYP2C9 substrates. In addition, metabolic enzyme inhibitors such as fluconazole may also increase the drug exposure of CYP2C9 ...
Shen Cheng, Darcy R. Flora, Mutaz M. Jaber, Allan E. Rettie, Richard C. Brundage, Timothy S. Tracy   +5 more
wiley   +1 more source

Genetic control of drug metabolism and drug action in man [PDF]

, 1985
The study of genetic factors that modify the individual response to drugs, referred to as "pharmacogenetics" is relatively new field, a discipline at the interface between genetic and clinical pharmacology.
Raghupati Sarma, G
core  

Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution Genome evolution and evolutionary systems biology [PDF]

, 2014
© 2014 Janha et al.; licensee BioMed Central Ltd.Background: Cytochrome P450 CYP2C19 metabolizes a wide range of pharmacologically active substances and a relatively small number of naturally occurring environmental toxins.
Janha, RE, Linton, KJ, Shaheen, SO, Sisay-Joof, F, Walton, RT, Worwui, A   +5 more
core   +3 more sources

Pharmacogenetics of Bronchodilator Response: Future Directions

, 2021
Joanne E. Sordillo, Rachel S. Kelly, Sharon M. Lutz, Jessica Lasky‐Su, Ann Chen Wu   +4 more
openalex   +2 more sources

Personalized care of paediatric drug‐resistant epilepsy in Africa: A single‐centre pilot study utilizing mobile health and genetic testing

Developmental Medicine &Child Neurology, EarlyView.
Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.70075 Abstract Aim To evaluate personalized care or precision medicine initiatives, including mobile health (mHealth) technology and genetic screening, in a South African paediatric epilepsy clinic. Method This exploratory prospective observational pilot study included 39 children
Ian S. Olivier, Karen Fieggen, Sandra Komarzynski, Elin H. Davies, Irene Muchada, Caitlin McIntosh, Alina Esterhuizen, Richard J. Burman, Jo M. Wilmshurst, And the University of Cape Town (UCT) Human Genetics Precision Medicine Epilepsy Group, Nicholas Loxton, Shrinav R Dawlatt, Akshay Vanmali   +12 more
wiley   +1 more source

Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria

Nature Communications
Erythropoietic protoporphyria (EPP) is a genetic disease characterized by protoporphyrin IX-mediated painful phototoxicity. Currently, options for the management of EPP-associated phototoxicity are limited and no oral medication is available.
Junjie Zhu, Fu-Ying Qin, Saifei Lei, Ruizhi Gu, Qian Qi, Jie Lu, Karl E. Anderson, Peter Wipf, Xiaochao Ma   +8 more
doaj   +1 more source